文献速递淋巴瘤

PARP14是STAT6突变型滤泡性淋巴瘤的新靶点

PARP14 is a novel target in STAT6 mutant follicular lymphoma.
PubMed 文献 · Leukemia · 2022-07-18

本研究在258例滤泡性淋巴瘤(FL)中发现13%(33/258)存在STAT6突变且均位于DNA结合域,突变型STAT6通过结合PARP14启动子增强其转录,形成自我强化调控环路,敲低PARP14或PARP抑制可消除STAT6突变的功能获得表型,提示PARP14为STAT6突变型FL的新治疗靶点。

要点

  • 258例滤泡性淋巴瘤中13%(33/258)检出STAT6突变,均聚集于DNA结合域。
  • STAT6突变型FL中IL-4/STAT6靶基因CCL17、CCL22、FCER2(CD23)表达上调。
  • PARP14是STAT6突变型FL中上调的基因,敲低PARP14或PARP抑制可消除其功能获得表型。

核心结论

  • PARP14是STAT6突变型滤泡性淋巴瘤的新治疗靶点。

研究设计与样本

  • 研究分析了258例滤泡性淋巴瘤样本的STAT6突变状态,并结合基因表达数据、免疫组化、前B集落形成单位连续铺板实验、RNA测序、定量染色质免疫沉淀和报告基因实验进行功能验证。

主要发现

  • 在13%(33/258)的滤泡性淋巴瘤中鉴定出STAT6突变,所有突变均聚集于DNA结合域。
  • 基因表达数据和免疫组化显示STAT6突变型FL中IL-4/STAT6靶基因CCL17、CCL22和FCER2(CD23)表达上调。
  • 前B集落形成单位连续铺板实验显示STAT6突变具有功能获得性表型。
  • STAT6突变增强IL-4诱导的FCER2/CD23、CCL17和CCL22表达,并与pSTAT6核内积聚相关。
  • RNA测序显示PARP14在IL-4刺激的STAT6突变型淋巴瘤细胞和STAT6突变型原代FL细胞中为差异上调的顶层基因之一。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The variable clinical course of follicular lymphoma (FL) is determined by the molecular heterogeneity of tumor cells and complex interactions within the tumor microenvironment (TME). IL-4 producing follicular helper T cells (TFH) are critical components of the FL TME. Binding of IL-4 to IL-4R on FL cells activates JAK/STAT signaling. We identified STAT6 mutations (STAT6MUT) in 13% of FL (N = 33/258), all clustered within the DNA binding domain. Gene expression data and immunohistochemistry showed upregulation of IL-4/STAT6 target genes in STAT6MUT FL, including CCL17, CCL22, and FCER2 (CD23). Functionally, STAT6MUT was gain-of-function by serial replating phenotype in pre-B CFU assays. Expression of STAT6MUT enhanced IL-4 induced FCER2/CD23, CCL17 and CCL22 expression and was associated with nuclear accumulation of pSTAT6. RNA sequencing identified PARP14 -a transcriptional switch and co-activator of STAT6- among the top differentially upregulated genes in IL-4 stimulated STAT6MUT lymphoma cells and in STAT6MUT primary FL cells. Quantitative chromatin immunoprecipitation (qChIP) demonstrated binding of STAT6MUT but not STAT6WT to the PARP14 promotor. Reporter assays showed increased IL-4 induced transactivation activity of STAT6MUT at the PARP14 promotor, suggesting a self-reinforcing regulatory circuit. Knock-down of PARP14 or PARP-inhibition abrogated the STAT6MUT gain-of-function phenotype. Thus, our results identify PARP14 as a novel therapeutic target in STAT6MUT FL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mentz M, Keay W, Strobl CD, et al. PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia. 2022. PMID: 35851155. doi:10.1038/s41375-022-01641-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。